Analysis of Pravastatin to prevent recurrence of atrial fibrillation after electrical cardioversion

被引：137

作者：

Tveit, A ^{[1
]}

Grundtvig, M

Gundersen, T

Vanberg, P

Semb, AG

Holt, E

Gullestad, L

机构：

[1] Asker & Baerum Hosp, Dept Internal Med, N-1309 Rud, Norway

[2] Innlandel Lillehammer Hosp, Dept Internal Med, Lillehammer, Norway

[3] Sorlandet Hosp, Dept Internal Med, Arendal, Norway

[4] Aker Univ Hosp, Dept Internal Med, Oslo, Norway

[5] Diakonhjemmet Hosp, Dept Internal Med, Oslo, Norway

来源：

AMERICAN JOURNAL OF CARDIOLOGY | 2004年 / 93卷 / 06期

关键词：

D O I：

10.1016/j.amjcard.2003.12.009

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

To test the hypothesis that a statin could reduce the recurrence rate of atrial fibrillation after electrical cardioversion (EC), we performed an open, controlled multicenter study. Patients (n = 114) who had atrial fibrilation >48 hours and who were scheduled for EC were randomized to receive 40 mg of provastatin once daily for 3 weeks before and 6 weeks after EC or no drug in addition to standard therapy. Pravastatin did not reduce the recurrence rate of atrial fibrillation after EC. (C) 2004 by Excepta Medica, Inc.

引用

页码：780 / 782

页数：3

共 12 条

[1] Effect of statin therapy on C-reactive protein levels - The Pravastatin Inflammation/CRP Evaluation (PRINCE): A randomized trial and cohort study [J].

Albert, MA ;

Danielson, E ;

Rifai, N ;

Ridker, PM .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (01) :64-70

[2] Lipid-lowering therapy for prevention of ventricular tachyarrhythmias [J].

Anderson, KP .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 42 (01) :88-92

[3] Downregulation of endocardial nitric oxide synthase expression and nitric oxide production in atrial fibrillation - Potential mechanisms for atrial thrombosis and stroke [J].

Cai, H ;

Li, ZM ;

Goette, A ;

Mera, F ;

Honeycutt, C ;

Feterik, K ;

Wilcox, JN ;

Dudley, SC ;

Harrison, DG ;

Langberg, JJ .

CIRCULATION, 2002, 106 (22) :2854-2858

[4] C-reactive protein elevation in patients with atrial arrhythmias - Inflammatory mechanisms and persistence of atrial fibrillation [J].

Chung, MK ;

Martin, DO ;

Sprecher, D ;

Wazni, O ;

Kanderian, A ;

Carnes, CA ;

Bauer, JA ;

Tchou, PJ ;

Niebauer, MJ ;

Natale, A ;

Van Wagoner, DR .

CIRCULATION, 2001, 104 (24) :2886-2891

[5] Plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 1321 patients with nonvalvular atrial fibrillation - Relationship to stroke risk factors [J].

Conway, DSG ;

Pearce, LA ;

Chin, BSP ;

Hart, RG ;

Lip, GYH .

CIRCULATION, 2002, 106 (15) :1962-1967

[6] C-reactive protein and paroxysmal atrial fibrillation: evidence of the implication of an inflammatory process in paroxysmal atrial fibrillation [J].

Dernellis, J ;

Panaretou, M .

ACTA CARDIOLOGICA, 2001, 56 (06) :375-380

[7] Effect of pravastatin on plasma markers of inflammation and peripheral endothelial function in male heart transplant recipients [J].

Holm, T ;

Andreassen, AK ;

Ueland, T ;

Kjekshus, J ;

Froland, SS ;

Kjekshus, E ;

Simonsen, S ;

Aukrust, P ;

Gullestad, L .

AMERICAN JOURNAL OF CARDIOLOGY, 2001, 87 (06) :815-+

[8]

Laufs U, 2000, CIRCULATION, V102, P3104

[9] Statins as potent antiinflammatory drugs [J].

Lefer, DJ .

CIRCULATION, 2002, 106 (16) :2041-2042

[10] Are lipid-lowering drugs also antiarrhythmic drugs? An analysis of the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial [J].

Mitchell, LB ;

Powell, JL ;

Gillis, AM ;

Kehl, V ;

Hallstrom, AP .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 42 (01) :81-87

← 1 2 →